Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) was the target of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 9,500 shares, a decrease of 67.2% from the October 31st total of 29,000 shares. Based on an average daily trading volume, of 22,000 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the company’s shares are sold short.
Analyst Ratings Changes
Several brokerages have recently weighed in on APRE. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research note on Monday, November 18th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.
Check Out Our Latest Stock Analysis on APRE
Aprea Therapeutics Stock Performance
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. Analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current year.
Insider Activity at Aprea Therapeutics
In related news, Director Bernd R. Seizinger acquired 10,000 shares of the stock in a transaction dated Friday, October 11th. The stock was bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the purchase, the director now directly owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This represents a 28.79 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Marc Duey bought 30,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were purchased at an average price of $4.39 per share, with a total value of $131,700.00. Following the acquisition, the director now directly owns 240,113 shares in the company, valued at approximately $1,054,096.07. This trade represents a 14.28 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 42,290 shares of company stock valued at $165,096. Company insiders own 12.80% of the company’s stock.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is owned by hedge funds and other institutional investors.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Read More
- Five stocks we like better than Aprea Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is a Dividend King?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.